Merck Serono v. TWI Pharmaceuticals: Federal Circuit Affirms Cladribine MS Patent Unpatentable
Merck Serono’s US7713947B2 — covering a cladribine dosing regimen for multiple sclerosis — was found unpatentable at the district level and that ruling was affirmed by the Federal Circuit in a 253-day appeal. The decision strengthens TWI Pharmaceuticals’ position and raises the bar for Merck Serono to enforce this MS treatment patent.
Federal Circuit closes the door on Merck Serono’s cladribine MS regimen patent
Merck Serono, SA — the originator of the cladribine-based multiple sclerosis treatment marketed as Mavenclad — appealed to the U.S. Court of Appeals for the Federal Circuit (Case No. 25-1463) seeking to overturn a finding that US7713947B2 was unpatentable. The patent, filed under application number US11/722018, covers a specific cladribine dosing regimen for treating relapsing forms of multiple sclerosis. The appeal was filed on 19 February 2025 and resolved by 30 October 2025.
The Federal Circuit affirmed the prior ruling, issuing a judgment that the cause had been considered and that the lower decision was affirmed outright. The basis of termination is recorded as ‘Unpatentable,’ meaning the court found that US7713947B2 does not meet the statutory requirements for patent protection. For TWI Pharmaceuticals, the affirmance clears a significant patent obstacle and may support its ability to develop or commercialise a generic or competing cladribine product for MS without infringing this specific patent.
The 253-day resolution — from filing to final judgment — is consistent with expedited Federal Circuit dockets in pharmaceutical patent disputes, suggesting the court did not find the appeal warranted extended briefing or oral argument complexity. What remains unknown from the public record is whether Merck Serono holds additional patents on cladribine formulations or methods of treatment that could separately restrict TWI’s commercialisation pathway, and whether Merck Serono intends to seek en banc rehearing or certiorari.
Filing to Unpatentable in 253 days
253 days from filing to Federal Circuit affirmance — within the typical 9–12 month appellate window for ANDA/pharma patent appeals
Federal Circuit affirms: what the unpatentability ruling means for both parties
What ‘AFFIRMED’ means at the Federal Circuit
An affirmance by the Federal Circuit means the appellate court reviewed the record and found no reversible error in the lower tribunal’s decision. The court is not required to agree with every aspect of the reasoning below — only to conclude that the outcome was legally and factually supportable. Here, the finding that US7713947B2 is unpatentable is now final at this appellate level, carrying significant precedential weight in any future challenge to this patent.
No reversible error foundMerck Serono loses federal circuit protection for cladribine regimen
For Merck Serono, the affirmance means US7713947B2 can no longer be enforced against TWI Pharmaceuticals or, effectively, any third party seeking to rely on this ruling. The patent’s unpatentability finding extinguishes the exclusivity that this specific claim could confer over the cladribine dosing regimen for MS. Merck Serono’s remaining commercial protection for Mavenclad would need to rely on other patents, regulatory exclusivities, or data protection periods not addressed in this case.
Enforceability extinguishedTWI Pharmaceuticals secures appellate validation of unpatentability
TWI Pharmaceuticals successfully defended the unpatentability finding through the Federal Circuit, the highest appellate court for U.S. patent matters short of the Supreme Court. This outcome substantially reduces TWI’s patent litigation risk with respect to this specific cladribine regimen patent. Merck Serono’s remaining appellate options — en banc rehearing or Supreme Court certiorari — are statistically unlikely to succeed and carry high procedural bars, meaning TWI can proceed with greater commercial certainty.
Appellate risk largely resolvedMS treatment market: raised bar for cladribine patent enforcement
The affirmance strengthens the precedent that this particular cladribine dosing regimen does not meet patentability standards, which may embolden other generic entrants evaluating MS treatment pipelines. Companies developing competing oral cladribine products should nonetheless conduct thorough FTO analyses against Merck Serono’s broader patent portfolio, as unpatentability of one claim set does not necessarily clear the entire IP landscape. The ruling is consistent with Federal Circuit trends scrutinising method-of-treatment claims in established pharmaceutical classes.
Generic pathway signal strengthenedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Merck Serono, SA | Company | Pharmaceutical innovator — holder of US7713947B2 (cladribine MS dosing regimen)Search in Eureka ↗ |
| Defendant | TWI Pharmaceuticals, Inc. | Company | TWI Pharmaceuticals, Inc. — generic/specialty pharma company defending invalidity findingSearch in Eureka ↗ |
| Plaintiff counsel | David B. Bassett | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Emily R. Whelan | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Gary M. Fox | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Helena Rachael MillionPerez | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | James M. Lyons | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Jennifer L. Graber | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Mark Christopher Fleming | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff counsel | Nora N. Xu | Attorney | Counsel for Merck Serono, SASearch in Eureka ↗ |
| Plaintiff law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Merck Serono, SASearch in Eureka ↗ |
| Defendant counsel | Donald J. Mizerk | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Philip D. Segrest | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen Reid Howe | Attorney | Counsel for TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Husch Blackwell LLP | Law Firm | Representing TWI Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a merits affirmance, not a procedural dismissal. The court reviewed the unpatentability finding and identified no reversible legal error under the applicable appellate standard of review, which typically requires clear error for factual findings and de novo review for legal conclusions on patentability. The unambiguous ‘AFFIRMED’ language leaves no room for remand or further fact-finding; the invalidity of US7713947B2 is conclusively established at this appellate level for both parties.
US7713947B2 — Cladribine oral dosing regimen for multiple sclerosis
US7713947B2, filed under application number US11/722018, protects a specific cladribine dosing regimen for the treatment of multiple sclerosis. Cladribine is a purine nucleoside analogue that selectively depletes lymphocytes, and its oral formulation — marketed by Merck Serono as Mavenclad — represented a significant advance over earlier intravenous and subcutaneous administrations. The patent’s claims centre on a defined treatment protocol rather than the molecule itself, placing it squarely within the method-of-treatment patent category that the Federal Circuit scrutinises heavily for obviousness over prior art dosing studies.
Strategically, US7713947B2 was Merck Serono’s key IP barrier against generic cladribine entrants seeking to replicate the Mavenclad dosing regimen. Its invalidation is commercially significant: it signals that the specific treatment protocol was not sufficiently inventive over the prior art, potentially opening the door for TWI and others to develop competing oral cladribine MS therapies. Innovators and generic developers in the MS space should note that method-of-treatment patents built on known molecules with documented prior art dosing regimens carry elevated invalidity risk at both PTAB and Federal Circuit levels.
Should your MS programme run an FTO against US7713947B2?
Any R&D or product team developing an oral cladribine therapy for multiple sclerosis — or evaluating a generic or biosimilar entry strategy — should assess this ruling’s scope carefully. While US7713947B2 has been held unpatentable, Merck Serono’s broader cladribine patent estate may include formulation patents, additional method claims, or continuation applications that remain in force. A focused FTO analysis should map all active patent families citing the same priority application and any continuations filed after US11/722018.
PatSnap Eureka’s FTO Search Agent can rapidly canvas Merck Serono’s full cladribine patent portfolio, identify related family members and continuations, and flag active claims that could still pose infringement risk for an oral MS product. Eureka’s AI-powered claim mapping allows IP and R&D teams to visualise claim overlap against a proposed product design — reducing time-to-clearance and ensuring no related patent family is overlooked before a commercialisation decision.
Run a freedom-to-operate analysis on US7713947B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in pharmaceutical method-of-treatment patent disputes
Cases where the Federal Circuit reviewed unpatentability findings in pharmaceutical method-of-treatment and MS or neurology drug patent disputes, comparable to Case 25-1463.
What this case signals for the multiple sclerosis drug IP landscape
The Federal Circuit’s affirmance in Merck Serono v. TWI Pharmaceuticals has immediate implications for cladribine patent enforcement and MS treatment competition.
Method-of-treatment patents for MS regimens face heightened Federal Circuit scrutiny
The affirmance of unpatentability for US7713947B2 is consistent with a Federal Circuit pattern of rigorously applying patentability standards to pharmaceutical dosing regimen claims. IP teams defending or asserting similar method-of-treatment patents in neurology and MS therapy should audit claim scope against obviousness and prior art risks before initiating or defending infringement actions.
Generic cladribine developers should still conduct portfolio-wide FTO before launch
While US7713947B2 is now unpatentable, Merck Serono’s broader IP estate around cladribine — including formulation, manufacturing, and additional method patents — may not be affected by this ruling. Any company targeting the oral cladribine MS market should commission a comprehensive FTO analysis covering all active Merck Serono patent families, not just the litigated claim set.
Merck v TWI — key questions answered
The Federal Circuit affirmed the lower tribunal’s finding that US7713947B2 — Merck Serono’s patent covering a cladribine dosing regimen for multiple sclerosis — is unpatentable. The court found no reversible error in the prior decision. The ruling is final at the Federal Circuit level, though Merck Serono could petition for en banc rehearing or Supreme Court certiorari.
US7713947B2 (application no. US11/722018) covers a specific cladribine oral dosing regimen for treating relapsing forms of multiple sclerosis. Cladribine selectively depletes lymphocytes and is the active ingredient in Merck Serono’s Mavenclad. The patent’s claims address the treatment protocol — dosing schedule and administration — rather than the molecule itself, making it a method-of-treatment patent.
Not necessarily. The ruling invalidates US7713947B2 specifically but does not affect any other patents in Merck Serono’s cladribine portfolio, including formulation or additional method-of-treatment patents. Generic developers should conduct a full freedom-to-operate analysis across all active Merck Serono patent families before assuming clear commercialisation rights. Regulatory exclusivities may also independently restrict market entry.
The Federal Circuit typically applies a de novo standard to legal conclusions on patentability — including obviousness as a question of law — while reviewing underlying factual findings for clear error. An affirmance indicates the court found neither legal error nor clearly erroneous factual determinations in the lower tribunal’s unpatentability analysis of US7713947B2.
Merck Serono may petition the full Federal Circuit for en banc rehearing, arguing the panel decision conflicts with prior Federal Circuit precedent or involves a question of exceptional importance. Alternatively, it could petition the U.S. Supreme Court for a writ of certiorari. Both avenues carry very low grant rates. Commercially, Merck Serono may rely on remaining portfolio patents, regulatory data exclusivity, or market exclusivity periods to protect Mavenclad’s position.
PatSnap Eureka searches patents and litigation data to answer instantly.